Evidence map›Paper›PMID 42170363›Full record

ArticleCureus2026

Early Predictors of Steroid Failure in Acute Severe Ulcerative Colitis: A Retrospective Study With the Evaluation of the Admission Model for Intensification of Therapy in Acute Severe Colitis (ADMIT-ASC) Score.

Othmane Merzouki, Saad Mliyahe, Houda Meyiz, Imane El Fadli, Manal Aziz, Yasmine Ghannami, Hassan Ouaya, Aicha Akjay, Ihssan Mellouki

Abstract read
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Othmane MerzoukiGastroenterology and Hepatology Department, Mohammed VI University Hospital, Tangier, MAR.
Saad MliyaheGastroenterology and Hepatology Department, Mohammed VI University Hospital, Tangier, MAR.
Houda MeyizGastroenterology and Hepatology Department, Mohammed VI University Hospital, Tangier, MAR.
Imane El FadliGastroenterology and Hepatology Department, Mohammed VI University Hospital, Tangier, MAR.
Manal AzizGastroenterology and Hepatology Department, Mohammed VI University Hospital, Tangier, MAR.
Yasmine GhannamiGastroenterology and Hepatology Department, Mohammed VI University Hospital, Tangier, MAR.
Hassan OuayaGastroenterology and Hepatology Department, Mohammed VI University Hospital, Tangier, MAR.
Aicha AkjayGastroenterology and Hepatology Department, Mohammed VI University Hospital, Tangier, MAR.
Ihssan MelloukiGastroenterology and Hepatology Department, Mohammed VI University Hospital, Tangier, MAR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsAcute severe ulcerative colitis (ASUC) is a life-threatening gastroenterological emergency in which early identification of patients at risk of corticosteroid failure is critical for timely therapeutic escalation. This study aimed to identify early predictive factors of corticosteroid failure and to evaluate the performance of the Admission Model for Intensification of Therapy in Acute Severe Colitis (ADMIT-ASC) score in predicting therapeutic failure in a North African cohort.

methodsThis was a retrospective, single-center study. Patients hospitalized for ASUC between September 2021 and January 2026 with complete data for ADMIT-ASC calculation were included (n = 87). The primary outcome was corticosteroid failure, defined as the requirement for rescue anti-TNF therapy or emergency colectomy during the same index hospitalization. Disease severity was assessed using the Truelove and Witts (TW) criteria, the Lichtiger score, the Ulcerative Colitis Endoscopic Index of Severity (UCEIS), the Oxford criteria (Travis score), and the ADMIT-ASC score. Fisher's exact test was used when expected cell counts were below 5; the chi-square (χ²) test otherwise.

resultsOf 87 patients included, 53 (60.9%) achieved clinical remission under intravenous corticosteroids; 27 patients (31.0%) required rescue therapy during the index hospitalization: 21 received anti-TNF rescue therapy (primarily infliximab 5 mg/kg), and 6 (6.9%) underwent emergency surgical colectomy; and the remaining 7 (8.1%) patients had incomplete outcome documentation in the hospital records, were retained in the denominator, and were excluded from the primary outcome analysis. The presence of more than two additional TW criteria (including fever, tachycardia, anemia, and elevated CRP beyond stool frequency) was the strongest admission predictor (χ² = 11.44, OR = 7.27 (95% CI: 2.37-22.31), p = 0.001). The ADMIT-ASC score ≥ 3 was significantly associated with failure (χ² = 4.34, OR = 3.92 (95% CI: 1.20-12.80), p = 0.037; sensitivity of 33.3% (95% CI: 18.6-52.2%), specificity of 88.7% (95% CI: 77.4-94.7%)). In a Firth penalized logistic regression, including both admission predictors, both remained independently associated with failure: adjusted OR 7.37 (95% CI: 2.35-23.12) for additional TW criteria and 5.10 (95% CI: 1.44-18.07) for ADMIT-ASC ≥ 3 (p = 0.012). The Lichtiger score ≥ 11 showed a trend toward significance without reaching it (p = 0.114). The UCEIS ≥ 7 was not significantly associated with failure (p = 0.631). The Travis score at day three remained the strongest predictor overall (OR = 153.1; p < 0.001).

conclusionsTraditional clinical markers at admission - particularly the number of additional TW criteria - remain highly effective predictors of corticosteroid failure. The ADMIT-ASC score is a promising adjunct for structured early risk stratification, with a high specificity (88.7%), complementing rather than replacing traditional clinical assessment and the Travis score at day three.

Indexed as

acute severe ulcerative colitisanti-tumor necrosis factorgastroenterology and endoscopypredictive scoringsteroid refractory

Identifiers

PMID42170363
PMCPMC13189035

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.